Medical Weight Loss
Physician-managed weight loss — including GLP-1 medications like semaglutide and tirzepatide — with labs, dosing and monitoring.
Medical Weight Loss clinics closest to you
Each of these names medical weight loss on its own website. We don't infer it from a clinic's type or category.
Juvly Aesthetics
Blue Sky Med Spa
ELMNTL
Reconstructive Body Arts
Hydrate Me Medspa - Grandview
Jiva Med Spa Columbus
The Luxe Medspa Aesthetics & Bodycare
Bonza Health
Buckeye Physical Medicine & Rehab
Fade Aesthetics And Wellness
Robert Heck, MD
Beyond Skin Aesthetics
Columbus Aesthetic & Plastic Surgery
Six and Luna Medspa
pēkomd: Peter Koltz, MD
Ideal Weight Loss & Cosmetic Centers
Nurture Aesthetics & Wellness
Retro Health and Aesthetics
O'Brien Medicine
Sol Wellness and Aesthetics
Donaldson Plastic Surgery & Aesthetic Solutions
BB Aesthetic & Wellness
MOBO Medical Spa LLC
Bijou Wellness Lounge
Reverse Aesthetics
Wellness ReSolutions
The Med Spa at Your Concierge MD
Dr. Mantor's Wrinkle and Weight Solutions
Pure Health Aesthetics & Wellness
Affinity Whole Health
Central Ohio Aesthetics Clinic
Renovaré Aesthetics and Wellness
4,747 more clinics offer medical weight loss — browse by city below, or start from a state:AlaskaAlabamaArkansasArizonaCaliforniaColoradoConnecticutWashington, D.C.DelawareFloridaGeorgiaHawaiiIowaIdahoIllinoisIndianaKansasKentuckyLouisianaMassachusettsMarylandMaineMichiganMinnesotaMissouriMississippiMontanaNorth CarolinaNorth DakotaNebraskaNew HampshireNew JerseyNew MexicoNevadaNew YorkOhioOklahomaOregonPennsylvaniaRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahVirginiaVermontWashingtonWisconsinWest VirginiaWyoming
Weight-loss program models, compared
The GLP-1s get the headlines (they're compared product-by-product on our peptide therapy page); this table is the wider menu a medical weight-loss clinic can legitimately offer, with what each achieved in trials against the lifestyle-only baseline.
| GLP-1 program | Phentermine | Qsymia | Contrave | Orlistat | |
|---|---|---|---|---|---|
| Approval | Long-term, adults and adolescents 12+ | Short-term only — a few weeks | Long-term | Long-term | Long-term |
| Trial result | 17.3% average loss at 68 weeks (semaglutide, STEP 1) | Label: excess loss over placebo is a fraction of a pound a week | 75% of patients lost ≥5%; ~8.8 kg excess loss | 55% lost ≥5%; ~5 kg excess | 44% lost ≥5%; ~2.6 kg excess |
| Notable cautions | Boxed warning (thyroid C-cell tumors); stop 2 months before planned pregnancy | Tolerance develops within weeks — the label says discontinue, don't escalate; contraindicated in heart disease | Highest-ranked older agent | Highest dropout from side effects in the network meta-analysis | Lowest efficacy of the approved agents |
| Lifestyle-only baseline | Placebo arms: ~2% loss at 68 weeks; a quarter of participants reach 5% | — | — | — | — |
The clearest data on discontinuation comes from the STEP 1 extension: participants who lost 17.3% on semaglutide regained about two-thirds of it within a year of stopping, and their cardiometabolic improvements reverted toward baseline. The study's own conclusion is that ongoing treatment is required to maintain the benefit. That transforms the cost question — the honest price of a GLP-1 program is a yearly figure for as long as you want the result, not a course with an end date, and any clinic selling a “12-week transformation” is selling the part of the curve that reverses.
Source: Wilding et al., Diabetes, Obesity and Metabolism, 2022 (STEP 1 trial extension) ↗The approved GLP-1 weight-loss products are indicated for adults with a BMI of 30 or more, or 27 or more with at least one weight-related condition — the same thresholds phentermine's label uses for its few-weeks indication. Labels also carry the exclusions clinics sometimes skip: the boxed warning against use with personal or family history of medullary thyroid carcinoma or MEN 2, discontinuation at least two months before a planned pregnancy, and glucose monitoring for patients with diabetes. A telehealth intake that doesn't establish your BMI, history, and medications isn't a medical screening; the FDA's own red-flag list for GLP-1 sellers includes exactly that.
Source: Wegovy prescribing information / FDA — concerns with unapproved GLP-1 drugs ↗Under the temporary Medicare GLP-1 Bridge that began July 1, 2026, Medicare covers Wegovy, Zepbound (KwikPen), and Foundayo for weight management at a $50 monthly copay — with strict gates: BMI 35+, or 30+ with specific conditions (diastolic heart failure, uncontrolled hypertension, stage 3a+ kidney disease), or 27+ with prediabetes or established cardiovascular disease, all with prior authorization and a certified diet-and-exercise program. Type 2 diabetes and sleep-apnea patients route through different coverage. Commercial insurance varies widely. If a clinic quotes you cash prices without mentioning the Bridge and you're on Medicare, they haven't done the homework.
Source: Medicare.gov — weight-loss drug coverage ↗Medical Weight Loss: common questions
Do I qualify for medical weight-loss treatment?
The FDA labels set the bar, not the clinic: BMI of 30 or more, or 27 or more with at least one weight-related condition such as hypertension or prediabetes — the same thresholds for the GLP-1s and the older oral agents. The exclusions matter as much: GLP-1s carry a boxed warning against use with a personal or family history of medullary thyroid cancer or MEN 2, and must be stopped at least two months before a planned pregnancy. A real program establishes all of this before prescribing; the FDA's own red-flag list for GLP-1 sellers starts with no screening by a licensed clinician.
Is compounded semaglutide still legal?
The window has closed. Compounded copies were permitted while the brand drugs were in shortage; the FDA declared the tirzepatide shortage resolved in late 2024 and semaglutide in early 2025, enforcement discretion ended in spring 2025, and courts declined to block it. As of 2026, neither drug is on the shortage or bulks lists, meaning mass-produced compounded versions no longer have a legal basis — the narrow exceptions are genuinely individualized prescriptions and tiny volumes. The FDA has logged over 990 adverse-event reports for compounded semaglutide; if a clinic's price seems impossible, ask which pharmacy fills it and whether the product is the FDA-approved drug.
What happens when I stop taking a GLP-1?
Most of the weight comes back. In the STEP 1 extension study, participants who had lost 17.3% on semaglutide regained about two-thirds of it within a year of stopping, and blood-pressure and metabolic improvements reverted toward baseline. The researchers' conclusion: ongoing treatment is required to maintain the benefit. Budget and plan on that basis — the honest cost of a GLP-1 program is annual and open-ended, and a clinic selling a short “course” is selling the reversible part of the curve.
Does insurance or Medicare cover weight-loss medication?
Commercial coverage varies widely by plan. Medicare changed materially on July 1, 2026: the temporary GLP-1 Bridge covers Wegovy, Zepbound (KwikPen), and Foundayo at a $50 monthly copay — gated by BMI 35+, or 30+ with conditions like uncontrolled hypertension or stage 3+ kidney disease, or 27+ with prediabetes or cardiovascular disease, with prior authorization and a certified diet-and-exercise program. Patients with type 2 diabetes or moderate-to-severe sleep apnea route through other coverage. If you're on Medicare, ask any clinic quoting cash prices why they haven't mentioned the Bridge.
What about the older, cheaper weight-loss pills?
They're real options with honest limits, ranked in a 28-trial network meta-analysis: phentermine-topiramate (Qsymia) performed best of the older agents — 75% of patients lost at least 5%, about 8.8 kg over placebo — followed by naltrexone-bupropion (Contrave), which also had the highest dropout from side effects, and orlistat at the bottom. Plain phentermine, the most-prescribed of all, is approved only for a few weeks of use: its label says tolerance develops quickly and the drug should then be discontinued, not dose-escalated, and it's contraindicated with heart disease. None approaches GLP-1 results, and all beat lifestyle-only baselines, where about a quarter of trial participants reach 5% loss.
What should a legitimate telehealth weight-loss program look like?
The FDA published its own red-flag list for GLP-1 sellers, and it doubles as a checklist: a licensed clinician screens you and writes a real prescription; someone is reachable after the medication arrives; the price isn't too good to be true; the product isn't marketed as “the same as” the brand drug; the label has no spelling errors or wrong pharmacy address; and injectables arrive cold, because they require refrigeration. Add the clinical basics — BMI and history taken, glucose monitoring if diabetic, a plan for the diet-and-exercise component the labels require — and you have a fair standard for judging any program.
How to choose a longevity clinic
What to look for
- Physician-led — clinicians you can look up by name and license
- Baseline lab work before any prescription or protocol
- Transparent, all-in pricing — including labs and follow-ups
- A clear plan for monitoring and adjusting your results over time
- A plan built around your goals, not a one-size-fits-all package
Be wary of
- Treatments (NAD+, peptides, hormones) pushed before any diagnostics
- “Reverse aging” or guaranteed-outcome claims
- Prescriptions written without recent lab work